Hyponatremia in Cirrhosis--Pathogenesis, Treatment, and Prognostic Significance.
|
| Abstract |
Cirrhosis is characterized by systemic and splanchnic vasodilation that leads to excessive nonosmotic secretion of vasopressin (antidiuretic hormone). Hyponatremia is a common electrolyte abnormality in advanced liver disease that results from the impaired ability of the kidney to excrete solute-free water that leads to "dilutional" hyponatremia-water retention disproportionate to the retention of sodium. Hyponatremia in liver diseases carries the prognostic burden, correlates with the severity of cirrhosis, and, in recent studies, has also been implicated in the pathogenesis of hepatic encephalopathy. The current treatment options are limited to conventional therapies like fluid restriction, and the outcomes are unsatisfactory. Although currently available vasopressin (V2 receptors) antagonists have been shown to increase serum sodium concentrations and improve ascites control, their role in the treatment of hyponatremia in liver disease patients remains questionable because of adverse effect profiles, high cost, and poor data on long-term mortality benefits. More information is needed to argue the benefits vs risks of short-term use of vaptans for correction of hyponatremia especially just hours-to-days before liver transplant.
|
|---|---|
| Authors | Vikash K Sinha, Benjamin Ko |
| Journal | Advances in chronic kidney disease (Adv Chronic Kidney Dis) Vol. 22 Issue 5 Pg. 361-7 (Sep 2015) ISSN: 1548-5609 [Electronic] United States |
| PMID | 26311597 (Publication Type: Journal Article, Review) |
| Copyright | Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!